LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--April 19, 2006--BioSante Pharmaceuticals, Inc. (Amex:BPA - News) announced today that its new drug application (NDA) for Bio-E-Gel (transdermal estradiol gel), an innovative low-dose topical therapy for moderate-to-severe hot flashes in menopausal women, has been accepted for filing and review by the U.S. Food and Drug Administration (FDA).
